Subscribe

Deep Dives

Danaher Corporation (DHR) Valuation Exercise

Danaher Corporation (DHR) brands

Danaher Corporation (DHR) reported earnings for the first quarter on 25th April. The report came in below guidance, resulting in the share price dropping.

Here are Biocompounding, we have been waiting for a pullback in Biotech picks & shovels plays to establish our position.

Following the report, we went through a valuation exercise to determine at what prices the company looks attractive and is a potential buy.

We first went through our valuation exercise on 27th Jan. Based on the reverse DCF seen below.

1) FCF - $7367Million

2) Growth rate of 7% cascading down to 3%

3) Discount rate of 8%

Read next

Intuitive Surgical

Crucial Metrics to Monitor for Intuitive Surgical and a Valuation Analysis

A few months ago, we conducted an in-depth analysis of Intuitive Surgical (ISRG) and performed a preliminary valuation. In our most recent research, we dedicated time to a more comprehensive examination of Intuitive Surgical's growth prospects and financials. Our goal was to identify the essential factors that shape

Ascendis Pharma (ASND): Redefining Drug Delivery with TransCon

Introduction Ascendis Pharma is a biopharmaceutical company applying its TransCon technology to develop a pipeline of long-acting prodrug therapies with best-in-class profiles to address large markets with significant unmet medical needs. The company was founded in 2007 and is headquartered in Copenhagen, Denmark, with offices in the United States. The

Halozyme Therapeutics (HALO): Bets on Licensing Model to Drive Growth

Halozyme Therapeutics (HALO): Bets on Licensing Model to Drive Growth

Introduction Halozyme Therapeutics is a biotechnology company that was co-founded in 1998 by Dr. Gregory Frost and subsequently listed in 2014. Halozyme’s focus was on oncology therapies and drug delivery technologies based on its proprietary recombinant human hyaluronidase enzyme, rHuPH20, but following the failure of its oncology drug, the